FDA approves Abbott imaging platform that uses artificial intelligence
Aug. 4, 2021
Abbott announced it has received U.S. Food and Drug Administration (FDA) clearance for an optical coherence tomography (OCT) imaging platform, which uses artificial intelligence (AI) to provide physicians with an enhanced, comprehensive view of coronary blood flow and blockages.
U.S. clearance follows the recently attained CE Mark in Europe, providing broader access to the platform for interventional cardiologists.
Ultreon Software integrates with Abbott's Dragonfly OpStar imaging catheter and PressureWire X guidewire to provide physicians access to a broad set of tools to assess coronary blood flow and blockages and improve treatment planning for patients.
